471820 — Cellromax Science Co Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeMicro CapNeutral

Annual income statement for Cellromax Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	18,837	21,086	19,310	21,630	22,184
Cost of Revenue
Gross Profit	8,783	9,853	9,755	12,284	10,547
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	13,728	14,476	14,689	16,126	19,372
Operating Profit	5,110	6,610	4,621	5,505	2,812
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,035	5,938	5,655	5,136	3,451
Provision for Income Taxes
Net Income After Taxes	3,984	4,732	4,499	3,817	2,966
Net Income Before Extraordinary Items
Net Income	3,984	4,732	4,499	3,817	2,966
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,984	4,732	4,499	3,817	2,984
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	342	406	390	327	262
Dividends per Share